Compare Pfizer Inc (PFE) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Visa Inc — how do they compare? Pfizer Inc trades at $28.23 (market cap $158.56B), while Visa Inc trades at $385.4 (market cap $704.20B). The key difference: Visa Inc is far larger — about 4.4× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Visa Inc for 115 Days on average.
| PFE | V | |
|---|---|---|
Market Cap | $158.56B | $704.20B |
Volume | 44,138,282 | 6,405,857 |
Sector | Health | Financials |
52-Week High | $29.02 | $384.14 |
52-Week Low | $23.67 | $295.52 |
Typical Hold Time | 158 Days | 115 Days |
Enterprise Value | $210.06B | $714.78B |
Dividend Yield | 6.18% | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Visa (V) trades at $385.45, up 3.59% today, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals, including a 50.78% net income margin and consistent earnings beats. Recent news highlights Visa's AI-driven initiatives like Intelligent Commerce Connect and partnerships to advance stablecoin adoption, positioning it for future growth in digital payments.
Outlook remains positive with a consensus price target of $422.24, implying 9.5% upside. Risks include competitive fintech threats and regulatory pressures. The company's high profitability and strategic focus on AI and digital payments support long-term investment appeal, though valuation multiples are elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
